ERLOTIVA

ERLOTIVA

Description

Capecitabine is a prodrug which metabolizes in higher concentrations in tumour cells to the active drug 5-Fluorouracil (5-FU). This is because an enzyme, thymidine phosphorylase, required in the last step of conversion to 5-FU is present in higher concentrations in certain cancer cells of breast, colon and rectum. The upregulation of thymidine phosphorylase by docetaxel makes it a synergistic combination with capecitabine. Capecitabine provides a valuable option in patients of metastatic breast cancer who are resisitant to anthracycline and paclitaxel-containing regimens or those for whom anthracyclines are contraindicated.

Indications:

• Erlotinib is prescribed as initial treatment for patients with NSCLC whose cancer has spread to other parts of the body and that has certain types of epidermal growth factor receptor (EGFR) mutations. (1st-line treatment)
• Prescribed as 2nd- or 3rd-line treatment for advanced-stage NSCLC in patients whose cancer has spread or grown after receiving at least one round of chemotherapy.
• Erlotinib in combination with gemcitabine is prescribed for patients with advanced-stage pancreatic cancer whose cancer has spread, grown, or cannot be surgically removed and who have not received previous chemotherapy.

Enquire Now